Comparing Rhythm Pharmaceuticals (NASDAQ:RYTM) and Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Earnings and Valuation

This table compares Soligenix and Rhythm Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$840,000.00	7.65	-$6.14 million	($7.53)	-0.34
Rhythm Pharmaceuticals	$77.43 million	45.86	-$184.68 million	($4.33)	-13.34

Soligenix has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Soligenix has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Soligenix and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	0	0	0	0	0.00
Rhythm Pharmaceuticals	0	1	10	0	2.91

Rhythm Pharmaceuticals has a consensus price target of $68.09, indicating a potential upside of 17.85%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Soligenix.

Insider and Institutional Ownership

3.6% of Soligenix shares are owned by institutional investors. 2.8% of Soligenix shares are owned by company insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Soligenix and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Soligenix	-1,473.38%	-223.29%	-74.18%
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%

Summary

Rhythm Pharmaceuticals beats Soligenix on 9 of the 14 factors compared between the two stocks.

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.